Source: United Kingdom – Executive Government & Departments
A paper, published in PNAS, reports on tocilizumab, an antibody, and whether it could be a treatment for COVID-19.
Dr Penny Ward, Visiting Professor in pharmaceutical medicine at Kings College London and the Chair of the Education and Standards Committee of the Faculty of Pharmaceutical Medicine, said:
“This is a very small case series investigating the outcomes following tocilizumab treatment in 24 severe cases of COVID-19 in China. Findings suggest that opposing IL-6 levels in these cases may be clinically beneficial. This needs to be confirmed in randomized controlled trials, which are underway.”
‘Effective treatment of severe COVID-19 patients with tocilizumab’ by Xiaoling Xu et al. was published in PNAS on Wednesday 29 April 2020.
All our previous output on this subject can be seen at this weblink: